Unknown

Dataset Information

0

The role of factor Xa inhibitors in venous thromboembolism treatment.


ABSTRACT: Three factor Xa inhibitors have been studied in the treatment of venous thromboembolism, both for acute therapy and as extended therapy to prevent recurrent events. Rivaroxaban, apixaban, and edoxaban have all proven to be effective in Phase III clinical trials for this indication when compared to current standard of therapy with similar or less bleeding. Nevertheless, the agents all offer different pharmacological profiles, which have an impact on patient selection and potential advantages in clinical practice.

SUBMITTER: Cabral KP 

PROVIDER: S-EPMC4321604 | biostudies-other | 2015

REPOSITORIES: biostudies-other

altmetric image

Publications

The role of factor Xa inhibitors in venous thromboembolism treatment.

Cabral Katherine P KP   Ansell Jack E JE  

Vascular health and risk management 20150130


Three factor Xa inhibitors have been studied in the treatment of venous thromboembolism, both for acute therapy and as extended therapy to prevent recurrent events. Rivaroxaban, apixaban, and edoxaban have all proven to be effective in Phase III clinical trials for this indication when compared to current standard of therapy with similar or less bleeding. Nevertheless, the agents all offer different pharmacological profiles, which have an impact on patient selection and potential advantages in c  ...[more]

Similar Datasets

| S-EPMC5539035 | biostudies-literature
| S-EPMC8130658 | biostudies-literature
| S-EPMC7513741 | biostudies-literature
| S-EPMC9234611 | biostudies-literature
| S-EPMC5541968 | biostudies-other
| S-EPMC2841004 | biostudies-literature
| S-EPMC5597622 | biostudies-literature
| S-EPMC7177540 | biostudies-literature
| S-EPMC9103187 | biostudies-literature
| S-EPMC6273828 | biostudies-literature